Subgroup analysis of the SAFE study suggested there may be a benefit in patients with severe sepsis (35% of whom had septic shock), with an adjusted odds ratio for death of 0.71 (95% CI, 0.52 to 0.97; P = 0.03) for albumin compared with saline [54]. The gene discussed is ALB; the disease is Sepsis.